Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00898365




Registration number
NCT00898365
Ethics application status
Date submitted
9/05/2009
Date registered
12/05/2009
Date last updated
11/11/2021

Titles & IDs
Public title
Study of Kidney Tumors in Younger Patients
Scientific title
Renal Tumors Classification, Biology, and Banking Study
Secondary ID [1] 0 0
NCI-2009-00416
Secondary ID [2] 0 0
AREN03B2
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Adult Cystic Nephroma 0 0
Anaplastic Kidney Wilms Tumor 0 0
Angiolipoma 0 0
Cellular Congenital Mesoblastic Nephroma 0 0
Classic Congenital Mesoblastic Nephroma 0 0
Clear Cell Sarcoma of the Kidney 0 0
Congenital Mesoblastic Nephroma 0 0
Cystic Partially Differentiated Kidney Nephroblastoma 0 0
Diffuse Hyperplastic Perilobar Nephroblastomatosis 0 0
Extrarenal Rhabdoid Tumor 0 0
Kidney Medullary Carcinoma 0 0
Kidney Neoplasm 0 0
Kidney Oncocytoma 0 0
Kidney Wilms Tumor 0 0
Metanephric Adenofibroma 0 0
Metanephric Adenoma 0 0
Metanephric Stromal Tumor 0 0
Metanephric Tumor 0 0
Mixed Congenital Mesoblastic Nephroma 0 0
Ossifying Renal Tumor of Infancy 0 0
Papillary Renal Cell Carcinoma 0 0
Renal Cell Carcinoma 0 0
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions 0 0
Rhabdoid Tumor of the Kidney 0 0
Wilms Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders
Cancer 0 0 0 0
Children's - Other
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - Cytology Specimen Collection Procedure
Other interventions - Laboratory Biomarker Analysis

Ancillary-correlative (renal tumor classification, biology) - Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)


Other interventions: Cytology Specimen Collection Procedure
Correlative studies

Other interventions: Laboratory Biomarker Analysis
Correlative studies

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Event-free survival - Time from diagnosis to the earliest occurrence of disease progression (if enrolling with measurable disease), first relapse (if enrolling without measurable disease), secondary malignancy, or death. Analysis plans are specific to individual COG-approved projects and biology protocols.
Timepoint [1] 0 0
Up to 5 years from study enrollment
Primary outcome [2] 0 0
Overall survival - Time from diagnosis to death. Analysis plans are specific to individual COG-approved projects and biology protocols.
Timepoint [2] 0 0
Up to 5 years from study enrollment
Secondary outcome [1] 0 0
Loss of heterozygosity (LOH testing discontinued as of April 2014) - Evaluation of LOH (1p and 16q) status was performed in select patients with newly diagnosed favorable histology Wilms Tumor during the time that AREN0532 and AREN0533 were open to enrollment, in order to direct patients to the appropriate therapeutic protocol and study arm as well as validate the markers' prognostic value.
Timepoint [1] 0 0
Baseline

Eligibility
Key inclusion criteria
- Patients with the first occurrence of any tumor of the kidney identified on CT scan or
MRI are eligible for this study; histologic diagnosis is not required prior to
enrollment but is required for all patients once on study

- Eligible tumors include (but are not limited to):

- Nephroblastic tumors

- Nephroblastoma (Wilms' tumor) (favorable histology, anaplasia [diffuse,
focal])

- Nephrogenic rests and nephroblastomatosis

- Cystic nephroma and cystic partially differentiated nephroblastoma

- Metanephric tumors (metanephric adenoma, metanephric adenofibroma,
metanephric stromal tumor)

- Mesoblastic nephroma (cellular, classic, mixed)

- Clear cell sarcoma

- Rhabdoid tumor (any malignant rhabdoid tumor occurring outside the central
nervous system [CNS])

- Renal epithelioid tumors of childhood (papillary renal cell carcinoma, medullary
renal cell carcinoma, renal tumors associated with Xp11.2 translocations,
oncocytic renal neoplasms after neuroblastoma)

- Angiolipoma

- Ossifying renal tumor of infancy

- Patients with the first occurrence of the following tumors are also eligible:

- Extrarenal nephroblastoma or extrarenal neprogenic rests

- Malignant rhabdoid tumor occurring anywhere outside the central nervous system

- Required specimens, reports, forms, and copies of imaging studies must be available or
will become available for submission and the institution must intend on submitting
them as described in the protocol procedures

- For ALL patients, (with exception of bilateral, bilaterally predisposed, multicentric,
or unilateral tumor in solitary kidney planning to enroll without biopsy***), the
following submissions are required:

- A complete set of recut hematoxylin and eosin (H & E) slides (including from
sampled lymph nodes, if patient had upfront nephrectomy)

- * Tissue must be from diagnosis, prior to any renal tumor directed
chemotherapy or radiation (only exception is for presumed favorable
histology Wilms tumor [FHWT] patients discovered to have diffuse anaplastic
Wilms tumor [DAWT] at delayed nephrectomy and plan to enroll at delayed
nephrectomy)

- Representative formalin-fixed paraffin-embedded tissue block or if a block is
unavailable, 10 unstained slides from a representative block of tumor, if
available.

- Tissue must be from diagnosis, prior to any renal tumor directed
chemotherapy or radiation (only exception is for presumed FHWT patients
discovered to have DAWT at delayed nephrectomy and plan to enroll at delayed
nephrectomy)

- Institutional pathology report, Specimen Transmittal Form, and Pre-Treatment
Pathology Checklist

- Copies of images and institutional reports of CT and/or MRI abdomen and pelvis,
and Pre Treatment Imaging Checklist

- Copies of images and institutional report of chest CT for all malignant tumors

- Institutional surgical report(s) and Pre-Treatment Surgical Checklist

- CRFs: Staging Checklist and Metastatic Disease Form (if metastatic disease is
noted on imaging)

- Patients with bilateral, bilaterally predisposed, multicentric, or
unilateral tumor in solitary kidney planning to enroll without biopsy via
imaging only - these patients will not have central review or have a risk
assignment issued, but may contribute to specimen banking for future
research. However, if biopsy is done, tissue must be submitted as for other
renal tumors, and initial risk assignment will require pathology and
surgical rapid central reviews. The Specimen Transmittal Form and Pre
Treatment Pathology Checklist are also needed.

- Please note: if the above required items are not received within 120 days of
study enrollment, the patient will be considered off study

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
Minimum age
No limit
Maximum age
29 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [3] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [4] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [5] 0 0
Royal Children's Hospital-Brisbane - Herston
Recruitment hospital [6] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [7] 0 0
Women's and Children's Hospital-Adelaide - North Adelaide
Recruitment hospital [8] 0 0
Monash Medical Center-Clayton Campus - Clayton
Recruitment hospital [9] 0 0
Royal Children's Hospital - Parkville
Recruitment hospital [10] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment hospital [11] 0 0
Perth Children's Hospital - Perth
Recruitment postcode(s) [1] 0 0
2310 - Hunter Regional Mail Centre
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
5006 - North Adelaide
Recruitment postcode(s) [7] 0 0
3168 - Clayton
Recruitment postcode(s) [8] 0 0
3052 - Parkville
Recruitment postcode(s) [9] 0 0
6008 - Perth
Recruitment postcode(s) [10] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
Arkansas
Country [5] 0 0
United States of America
State/province [5] 0 0
California
Country [6] 0 0
United States of America
State/province [6] 0 0
Colorado
Country [7] 0 0
United States of America
State/province [7] 0 0
Connecticut
Country [8] 0 0
United States of America
State/province [8] 0 0
Delaware
Country [9] 0 0
United States of America
State/province [9] 0 0
District of Columbia
Country [10] 0 0
United States of America
State/province [10] 0 0
Florida
Country [11] 0 0
United States of America
State/province [11] 0 0
Georgia
Country [12] 0 0
United States of America
State/province [12] 0 0
Hawaii
Country [13] 0 0
United States of America
State/province [13] 0 0
Idaho
Country [14] 0 0
United States of America
State/province [14] 0 0
Illinois
Country [15] 0 0
United States of America
State/province [15] 0 0
Indiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Iowa
Country [17] 0 0
United States of America
State/province [17] 0 0
Kansas
Country [18] 0 0
United States of America
State/province [18] 0 0
Kentucky
Country [19] 0 0
United States of America
State/province [19] 0 0
Louisiana
Country [20] 0 0
United States of America
State/province [20] 0 0
Maine
Country [21] 0 0
United States of America
State/province [21] 0 0
Maryland
Country [22] 0 0
United States of America
State/province [22] 0 0
Massachusetts
Country [23] 0 0
United States of America
State/province [23] 0 0
Michigan
Country [24] 0 0
United States of America
State/province [24] 0 0
Minnesota
Country [25] 0 0
United States of America
State/province [25] 0 0
Mississippi
Country [26] 0 0
United States of America
State/province [26] 0 0
Missouri
Country [27] 0 0
United States of America
State/province [27] 0 0
Nebraska
Country [28] 0 0
United States of America
State/province [28] 0 0
Nevada
Country [29] 0 0
United States of America
State/province [29] 0 0
New Hampshire
Country [30] 0 0
United States of America
State/province [30] 0 0
New Jersey
Country [31] 0 0
United States of America
State/province [31] 0 0
New Mexico
Country [32] 0 0
United States of America
State/province [32] 0 0
New York
Country [33] 0 0
United States of America
State/province [33] 0 0
North Carolina
Country [34] 0 0
United States of America
State/province [34] 0 0
North Dakota
Country [35] 0 0
United States of America
State/province [35] 0 0
Ohio
Country [36] 0 0
United States of America
State/province [36] 0 0
Oklahoma
Country [37] 0 0
United States of America
State/province [37] 0 0
Oregon
Country [38] 0 0
United States of America
State/province [38] 0 0
Pennsylvania
Country [39] 0 0
United States of America
State/province [39] 0 0
Rhode Island
Country [40] 0 0
United States of America
State/province [40] 0 0
South Carolina
Country [41] 0 0
United States of America
State/province [41] 0 0
South Dakota
Country [42] 0 0
United States of America
State/province [42] 0 0
Tennessee
Country [43] 0 0
United States of America
State/province [43] 0 0
Texas
Country [44] 0 0
United States of America
State/province [44] 0 0
Utah
Country [45] 0 0
United States of America
State/province [45] 0 0
Vermont
Country [46] 0 0
United States of America
State/province [46] 0 0
Virginia
Country [47] 0 0
United States of America
State/province [47] 0 0
Washington
Country [48] 0 0
United States of America
State/province [48] 0 0
West Virginia
Country [49] 0 0
United States of America
State/province [49] 0 0
Wisconsin
Country [50] 0 0
Canada
State/province [50] 0 0
Alberta
Country [51] 0 0
Canada
State/province [51] 0 0
British Columbia
Country [52] 0 0
Canada
State/province [52] 0 0
Manitoba
Country [53] 0 0
Canada
State/province [53] 0 0
Newfoundland and Labrador
Country [54] 0 0
Canada
State/province [54] 0 0
Nova Scotia
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Canada
State/province [56] 0 0
Quebec
Country [57] 0 0
Canada
State/province [57] 0 0
Saskatchewan
Country [58] 0 0
Israel
State/province [58] 0 0
Petah Tikua
Country [59] 0 0
New Zealand
State/province [59] 0 0
Auckland
Country [60] 0 0
New Zealand
State/province [60] 0 0
Christchurch
Country [61] 0 0
New Zealand
State/province [61] 0 0
Wellington
Country [62] 0 0
Puerto Rico
State/province [62] 0 0
San Juan
Country [63] 0 0
Switzerland
State/province [63] 0 0
Bern

Funding & Sponsors
Primary sponsor type
Other
Name
Children's Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This research trial studies kidney tumors in younger patients. Collecting and storing samples
of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may
help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify
biomarkers related to cancer.
Trial website
https://clinicaltrials.gov/show/NCT00898365
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Elizabeth A Mullen
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00898365